safe laser therapy for intraretinal bleeding

Not Applicable

Completed

• Conditions: Health Condition 1: null- Idiopathic Polypoidal Choroidal VasculopathyHealth Condition 2: H36- Retinal disorders in diseases classified elsewhere

• Registration Number: CTRI/2019/03/017901
• Lead Sponsor: V Prasad Eye Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-11-12
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 11

Inclusion Criteria

1.Patients of PCV who are treatment naïve or have received intra vitreal anti- VEGF injection (at least 6 months prior to being enrolled into the study).

2.Patients with best corrected visual acuity (BCVA) between 20/30 to 20/400.

Exclusion Criteria

1.Patients not giving consent for study

2.Patients who received any form of laser treatment before enrolment into the study including: focal laser photocoagulation, vertiporfin PDT, trans pupillary thermotherapy.

3.Patients who received any intravitreal injection within a period of 6 months prior to the enrolment time.

4.Patients with significant cataract or corneal opacity.

5.Patients having reduced vision due to any other retinal pathology.

6.Patients allergic to fluorescein or Indocyanine green (ICG).

7.Patients with extra macular polyps.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To determine the efficacy of micropulse laser in the treatment of PCVTimepoint: 12 months

Secondary Outcome Measures

Name	Time	Method
1.Proportion of patients achieving the polyp closure or regression (as described below) at the end of 12 months of enrolment into the study. <br/ ><br>2.Number of Anti- VEGF injections injected intravitreally <br/ ><br>3.Proportion of patients with no fluid on OCT. <br/ ><br>4.Gain of visual acuity from baseline. <br/ ><br>Timepoint: 12 months